FGF23 and chronic kidney disease: Soluble Klotho, a co-receptor for FGF23 with antioxidant and anti-inflammatory effects, declines progressively in CKD; low levels independently predict arterial stiffness and adverse cardiovascular outcomes in human CKD cohorts [216].